Stout Advises Healthmark Industries on Sale to Getinge AB

Stout announced today that its client, Healthmark Industries Company, Inc., has been acquired by Getinge AB for $320 million, representing a multiple of 17x estimated EBITDA for 2023. Getinge AB, founded in 1904 and based in Gothenburg, Sweden, is a leading global manufacturer of medical equipment and associated consumables used by hospitals for reprocessing and sterilization of surgical instruments and medical devices. It is also a leading manufacturer and marketer of equipment used in cardiac surgery, operating suites, and pharmaceutical production.

Founded in 1969 and based in Fraser, Michigan, Healthmark Industries is a leading manufacturer, marketer, and distributor of consumable medical devices and supplies used by sterile processing departments in hospitals for cleaning verification and sterile instrument packaging. In its fiscal year ending October 31, 2023, Healthmark expects revenue to increase 15% to $126 million.

Stout served as exclusive financial advisor to Healthmark in connection with this transaction.

Stout Managing Director John Calcagnini, who led the deal team, said, “The acquisition is expected to significantly enhance Getinge’s consumable offering to complement its sales of sterilization and reprocessing equipment, offering hospital customers a complete and best-in-class bundle of products and services designed to drive market share inroads.

“We also see an enormous opportunity for Getinge to expand distribution of Healthmark products to its’ international customers, as Healthmark generates 90% of revenue in the U.S. today. We don’t see why they could not grow the business to the point where international represents 50% of the mix, which is what we see with other large medical device manufacturers.”

Mark Basile, CEO of Healthmark, said, “We chose Stout for their expertise in medical devices and track record in managing cross-border transactions like ours, and that proved to be a great call. We would like to thank them for their leadership, efficiency, professionalism, knowledge, and excellent work in managing our process and putting together this important transaction. Stout’s assistance was irreplaceable, particularly in putting the finer points of the deal together and helping to map out the synergies. At the end of the day, Stout helped bring excellent value to the shareholders of Healthmark.”

Stout’s Eric Froidevaux, Max Halsted, Jake Kussin-Bordo, and Nate Lombard assisted in executing the deal.

Howard & Howard served as legal counsel to Healthmark. Covington and Burling LLP acted as legal counsel to Getinge AB.

SourceSTOUT

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.